AbbVie's Humira nabs orphan status in skin disease; GSK-backed poll boosts case for meningitis vaccines;

> AbbVie's ($ABBV) top-selling anti-inflammatory therapy Humira won an FDA orphan designation in the rare skin disease hidradenitis, making the drug eligible for 7 years of exclusivity in that indication. Report

> A new U.S. poll found that 83% of parents want their teens and young adults to be vaccinated against meningococcal disease; the survey was sponsored by GlaxoSmithKline ($GSK), which markets the men B shot Menhibrix. Release

> A generics maker is suing the FDA after the agency declared that its version of the Johnson & Johnson ($JNJ) ADHD med Concerta wasn't bioequivalent to the brand, nixing the copycat med's automatic substitution at pharmacies. Report

> The first set of American Urological Association guidelines for Peyronie's disease, in which scar tissue builds up in the penis, recommends Endo's ($ENDP) Xiaflex as a treatment option. Release

> Makovsky's health practice director Gil Bashe jumped ship to join rival PR firm Finn Partners, where he'll focus on growing the firm's business in biopharma. Report

> The health-focused communications agency KYNE recruited Novartis ($NVS) vet Maureen Byrne to head up its New York office. Report

And Finally... Merck KGaA could have trouble hitting healthcare heights. Report (sub. req.)

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

Telehealth is surging during the pandemic, however, pharma companies’ place in the booming practice is still emerging.

Merck is expanding its cancer awareness effort with journalist Katie Couric to include survivorship and screening topics and a new podcast next month.